Cargando…
The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis
The objective of this systematic literature review was to determine the association between cardiovascular events (CVEs) and antirheumatic drugs in rheumatoid arthritis (RA) and psoriatic arthritis (PsA)/psoriasis (Pso). Systematic searches were performed of MEDLINE, EMBASE and Cochrane databases (1...
Autores principales: | Roubille, Camille, Richer, Vincent, Starnino, Tara, McCourt, Collette, McFarlane, Alexandra, Fleming, Patrick, Siu, Stephanie, Kraft, John, Lynde, Charles, Pope, Janet, Gulliver, Wayne, Keeling, Stephanie, Dutz, Jan, Bessette, Louis, Bissonnette, Robert, Haraoui, Boulos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345910/ https://www.ncbi.nlm.nih.gov/pubmed/25561362 http://dx.doi.org/10.1136/annrheumdis-2014-206624 |
Ejemplares similares
-
Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept
por: Bessette, Louis, et al.
Publicado: (2023) -
Etanercept in the treatment of rheumatoid arthritis
por: Haraoui, Boulos, et al.
Publicado: (2007) -
Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry
por: Rahman, Proton, et al.
Publicado: (2017) -
Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis
por: Bulatović Ćalasan, Maja, et al.
Publicado: (2013) -
The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis
por: Pope, Janet E, et al.
Publicado: (2014)